Furosemide and Creatinine Tubular Stress Test in Order to Measure Proximal Tubule Residual Function
Primary Purpose
Chronic Kidney Failure
Status
Unknown status
Phase
Phase 3
Locations
Mexico
Study Type
Interventional
Intervention
Furosemide
Sponsored by
About this trial
This is an interventional diagnostic trial for Chronic Kidney Failure
Eligibility Criteria
Inclusion Criteria:
- Patients older than 18 years old.
- Patients with CKD that attends to the outpatient clinic.
- Residual uresis of 500 mL
Exclusion Criteria:
- Patients younger than 18 years old.
- Increase of Cr in a rate of 0.5 mg/dL, or loss of more than 30% of previous GFR.
- Patients with cardiorrenal syndrome type 1.
- Patients with dilated miocardiopathy.
- Volume overload.
Sites / Locations
- Instituto Nacional de Cardiologia Ignacio ChávezRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Healthy Kidney Donors
CKD Patients
Arm Description
12 Healthy Kidney Organ Donors
12 patients for each CKD Stage
Outcomes
Primary Outcome Measures
Tubular Residual Kidney Function
To assess the functionallity of the HOAT1 and 3, as well OCT2 by stress test using furosemide and creatinine loads
Secondary Outcome Measures
Full Information
NCT ID
NCT05105009
First Posted
March 11, 2020
Last Updated
October 22, 2021
Sponsor
Instituto Nacional de Cardiologia Ignacio Chavez
1. Study Identification
Unique Protocol Identification Number
NCT05105009
Brief Title
Furosemide and Creatinine Tubular Stress Test in Order to Measure Proximal Tubule Residual Function
Official Title
Furosemide and Creatinine Tubular Stress Test in Order to Measure Proximal Tubule Residual Function: Is it Better Than GFR?
Study Type
Interventional
2. Study Status
Record Verification Date
October 2021
Overall Recruitment Status
Unknown status
Study Start Date
March 3, 2020 (Actual)
Primary Completion Date
December 1, 2021 (Anticipated)
Study Completion Date
July 1, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Instituto Nacional de Cardiologia Ignacio Chavez
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a two phase study. The first part will take place at the National Institute of Cardiology in Mexico, the second phase will be made in collaboration with the University of California San Diego.
This is a non blind experimental study, 60 patients with different stages of CKD from the outpatient unit of the institute will be included. Each patient will receive a furosemide stress test of 1 mg/kg in non diuretic users and 1.5 mg/kg in diuretic users, in addition to an oral load of 5 grams of creatinine, as well as Iohexol to measure GFR. After the intervention blood and urine samples will be drawn at 10 minutes, 30 minutes, and every hour until the completion of the observation at 6 hours.
Blood and urine will be analized to measure creatinine (blood and urine), then samples will be processed for measurement of furosemide (mass spectometry), indoxyl sulphate, p-cresol, hippurate, and uromoduline.
The aim of this stiudy is to asses the differences between GFR and proximal tubule function.
Detailed Description
Residual kidney function (RKF) its a critical tool in the CKD evolution and prognosis. It's well known that preserving RKF increases survival in patients with CKD.
Traditionally Glomerular Filtration Rate (GFR), and proteinuria have been the variables used to asses RKF, wich are glomerular residual function (GRF) variables. This glomerulocentric assestment of RKF has been challenged recently. It is knows that urea is not the principal uremic toxine, the protein boud uremic toxins are particullary important because it's elimination depends of the proximal tubular organic anionic transporters (OAT), and the organic cationic transporters (OCT). The functional integrity of this transporters are lost in advanced CKD stages, and it´s accumulation increases cardiovascular and renal damage because they activate proinflammatory citokines, increasing mortality, this was shown specially with the accumulation and clearance of hippurate and p-cresol independently of GFR.
The purpose of this study is to asses the functional capacity of two AOT (hOAT1, and hOAT3, that can be blocked by furosemide), and one OCT (OCT2 blocked by creatinine) using an stress test. The stress test will be performed in healthy subjects as well as in CKD from different stages. Protein bound uremic toxins such as indoxyl sulphate, p-cresol, and hippurate will be measured.
In the stress the typical furosemide stress test described previously by Mehta will be implemented, in addition to an oral load of 5 grams of creatinine oral load. This levels should be efficient enough to assess the functionality of the OCT2. A comparison between the tubular creatinine secretine to filtrated creatinine measuring GFR using Iohexol will be performed.
In conclusion this is a pilot study aimed to establish a practical methodology for the assesment of proximal tubular function.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Kidney Failure
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
CKD Cohort with and control group of healthy kidney donors.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
72 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Healthy Kidney Donors
Arm Type
Active Comparator
Arm Description
12 Healthy Kidney Organ Donors
Arm Title
CKD Patients
Arm Type
Experimental
Arm Description
12 patients for each CKD Stage
Intervention Type
Drug
Intervention Name(s)
Furosemide
Other Intervention Name(s)
Creatinine
Intervention Description
Furosemide Stress Test ( 1mg/kg in non diuretic users and 1.5 mg/kg in diuretic users).
Oral creatinine load using 5 grams of creatinine
Primary Outcome Measure Information:
Title
Tubular Residual Kidney Function
Description
To assess the functionallity of the HOAT1 and 3, as well OCT2 by stress test using furosemide and creatinine loads
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Patients older than 18 years old.
Patients with CKD that attends to the outpatient clinic.
Residual uresis of 500 mL
Exclusion Criteria:
Patients younger than 18 years old.
Increase of Cr in a rate of 0.5 mg/dL, or loss of more than 30% of previous GFR.
Patients with cardiorrenal syndrome type 1.
Patients with dilated miocardiopathy.
Volume overload.
Facility Information:
Facility Name
Instituto Nacional de Cardiologia Ignacio Chávez
City
Mexico City
ZIP/Postal Code
14080
Country
Mexico
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Magdalena Madero, MD
Phone
015555732911
Ext
1273
Email
madero.magdalena@gmail.com
First Name & Middle Initial & Last Name & Degree
Armando Armenta, MD
Phone
015555732911
Ext
1273
Email
ar.armenta89@gmail.com
12. IPD Sharing Statement
Plan to Share IPD
Undecided
IPD Sharing Plan Description
Will be decided in the future
Learn more about this trial
Furosemide and Creatinine Tubular Stress Test in Order to Measure Proximal Tubule Residual Function
We'll reach out to this number within 24 hrs